Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
15.40
-0.51 (-3.21%)
Jul 8, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 90.77 | 60.18 | 105.6 | 145.65 | 123.55 | 293.83 |
Short-Term Investments | 163.25 | 187.04 | 264.93 | 400.58 | 516.6 | 320.97 |
Cash & Short-Term Investments | 254.02 | 247.22 | 370.53 | 546.22 | 640.15 | 614.79 |
Cash Growth | -15.66% | -33.28% | -32.17% | -14.67% | 4.13% | 0.36% |
Other Current Assets | 13.28 | 13.72 | 9.07 | 8.46 | 11.14 | 11.49 |
Total Current Assets | 267.3 | 260.94 | 379.59 | 554.69 | 651.3 | 626.29 |
Net Property, Plant & Equipment | 50.55 | 53.64 | 72.94 | 142.32 | 166.27 | 166.64 |
Long-Term Investments | 25.95 | 19 | 32.01 | 48.51 | 115.04 | 330.53 |
Other Long-Term Assets | 6.82 | 6.47 | 6.31 | 4.52 | 4.96 | 3.95 |
Total Assets | 350.63 | 340.05 | 490.86 | 750.03 | 937.56 | 1,127 |
Accounts Payable | 5.47 | 2.89 | 5.37 | 4.82 | 3.92 | 3.21 |
Accrued Expenses | 31.48 | 46.52 | 40.82 | 28.13 | 28.76 | 29.06 |
Unearned Revenue | - | - | - | - | - | 4.99 |
Other Current Liabilities | - | - | 7.6 | 1.58 | 4.36 | 9.49 |
Total Current Liabilities | 36.95 | 49.41 | 53.79 | 34.52 | 37.03 | 46.74 |
Long-Term Leases | 39.49 | 41.92 | 50.99 | 56.89 | 63.17 | 66.65 |
Other Long-Term Liabilities | 0.53 | 0.52 | 3.25 | 3.66 | 4.11 | 84.23 |
Total Long-Term Liabilities | 40.01 | 42.44 | 54.25 | 60.56 | 67.28 | 150.88 |
Total Liabilities | 76.96 | 91.85 | 108.04 | 95.08 | 104.31 | 197.62 |
Common Stock | 0 | 0 | 0 | 0.03 | 0.03 | 0.02 |
Additional Paid-in Capital | 1,917 | 1,868 | 1,728 | 1,657 | 1,608 | 1,516 |
Accumulated Other Comprehensive Income | -0.01 | 0.24 | 0.29 | -0.09 | -7.6 | -1.62 |
Retained Earnings | -1,644 | -1,620 | -1,345 | -1,002 | -767.48 | -584.36 |
Total Common Shareholders' Equity | 273.67 | 248.2 | 382.82 | 654.95 | 833.25 | 929.79 |
Shareholders' Equity | 273.67 | 248.2 | 382.82 | 654.95 | 833.25 | 929.79 |
Total Liabilities & Equity | 350.63 | 340.05 | 490.86 | 750.03 | 937.56 | 1,127 |
Total Debt | 39.49 | 41.92 | 50.99 | 56.89 | 63.17 | 66.65 |
Net Cash (Debt) | 214.54 | 205.3 | 319.53 | 489.33 | 576.98 | 548.14 |
Net Cash Growth | 4.50% | -35.75% | -34.70% | -15.19% | 5.26% | -2.41% |
Net Cash Per Share | 11.37 | 12.01 | 24.44 | 38.99 | 46.70 | 80.66 |
Book Value | 273.67 | 248.2 | 382.82 | 654.95 | 833.25 | 929.79 |
Book Value Per Share | 14.51 | 14.52 | 29.28 | 52.19 | 67.45 | 136.82 |
Tangible Book Value | 273.67 | 248.2 | 382.82 | 654.95 | 833.25 | 929.79 |
Tangible Book Value Per Share | 14.51 | 14.52 | 29.28 | 52.19 | 67.45 | 136.82 |